2025-05-17 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data, presented in a structured format.

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of innovative medicines and vaccines.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -1.11%
*   **VOO Cumulative Return:** 84.12%
*   **Absolute Divergence:** -85.23%
*   **Relative Divergence:** 0.0

**Analysis:** MRK has significantly underperformed the S&P 500 over the tracked period. The current divergence is at the lowest point of its historical range, indicating substantial underperformance relative to the benchmark.

| Year      | CAGR    | MDD   | Alpha    | Beta   | Cap(B) |
| --------- | ------- | ----- | -------- | ------ | ------ |
| 2015-2017 | 5.0%    | 58.4% | -24.0%   | 0.0    | 108.3  |
| 2016-2018 | 42.0%   | 66.6% | 24.0%    | 0.1    | 151.6  |
| 2017-2019 | 40.0%   | 66.6% | 11.0%    | 0.2    | 185.4  |
| 2018-2020 | 19.0%   | 66.6% | -6.0%    | 0.4    | 172.0  |
| 2019-2021 | -1.0%   | 65.6% | -55.0%   | 0.5    | 175.1  |
| 2020-2022 | 13.0%   | 69.3% | 7.0%     | 0.5    | 261.6  |
| 2021-2023 | 35.0%   | 69.3% | 19.0%    | 0.3    | 264.2  |
| 2022-2024 | -6.0%   | 69.3% | -23.0%   | 0.3    | 247.7  |
| 2023-2025 | -54.0%  | 73.1% | -86.0%   | 0.6    | 191.0  |

**Analysis:**

*   **CAGR:** The CAGR fluctuates significantly, with the most recent period (2023-2025) showing a substantial decline.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant risk exposure.
*   **Alpha:** Alpha is mostly negative, especially in recent periods, reflecting underperformance relative to the risk-free rate and market.
*   **Beta:** Beta values are relatively low (below 0.6), suggesting MRK is less volatile than the overall market.
*   **Cap(B):** Market capitalization has fluctuated over the periods, with the most recent period showing a considerable decrease.

### 2. Recent Price Action

*   **Current Price:** \$76.06
*   **Previous Close:** \$74.80
*   **Change:** \$1.68
*   **5-day Moving Average:** 76.28
*   **20-day Moving Average:** 79.68
*   **60-day Moving Average:** 85.40

**Analysis:** The current price is below the 5-day, 20-day, and 60-day moving averages, indicating a short-term downtrend. However, the recent price increase suggests a potential short-term rebound. The positive change from the previous close might be a temporary fluctuation.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3475 (Low Risk)
*   **RSI:** 35.97 (Approaching Oversold)
*   **PPO:** -0.4958 (Negative, indicating a downtrend)
*   **Delta_Previous_Relative_Divergence:** -7.0 (Short-term decline)
*   **Expected Return:** -1105.5% (Significant underperformance against the S&P 500)

**Analysis:** The MRI indicates low market risk, but the RSI is nearing oversold territory, suggesting the stock may be undervalued. The negative PPO and decline in relative divergence confirm the short-term downtrend. The significantly negative expected return highlights a long-term concern.

### 4. Recent News & Significant Events

*   **May 17, 2025:** Major business developments, regulatory changes, or market events.
*   **May 13, 2025:** Analysts discussing recent performance and outlook.
*   **May 14, 2025:** Notable stock volatility.
*   **May 15, 2025:** Market experts highlight both risks and opportunities.

**Analysis:** The news suggests recent events are influencing the stock's performance and volatility. Investors should closely monitor company announcements and market developments.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
| ---------- | ---- | ---------- |
| 2025-05-02 | 2.01 | 15.53 B\$  |
| 2024-11-06 | 1.25 | 16.66 B\$  |
| 2024-08-05 | 2.15 | 16.11 B\$  |
| 2024-05-03 | 1.88 | 15.78 B\$  |
| 2025-05-02 | 1.88 | 15.78 B\$  |

**Analysis:** Earnings Per Share (EPS) and revenue have fluctuated over the reported quarters. The most recent EPS is relatively strong, but revenue has slightly declined.

### 6. Financial Information

| Quarter    | Revenue  | Profit Margin |
| ---------- | -------- | ------------- |
| 2025-03-31 | \$15.53B | 77.98%        |
| 2024-12-31 | \$15.62B | 75.50%        |
| 2024-09-30 | \$16.66B | 75.51%        |
| 2024-06-30 | \$16.11B | 76.76%        |
| 2024-03-31 | \$15.78B | 77.56%        |

| Quarter    | Equity   | ROE      |
| ---------- | -------- | -------- |
| 2025-03-31 | \$48.34B | 10.51%   |
| 2024-12-31 | \$46.31B | 8.08%    |
| 2024-09-30 | \$44.50B | 7.09%    |
| 2024-06-30 | \$43.58B | 12.52%   |
| 2024-03-31 | \$40.36B | 11.80%   |

**Analysis:** Revenue shows some volatility, with a recent dip. Profit margins are consistently high, indicating strong profitability. Equity has generally increased, but Return on Equity (ROE) has fluctuated.

### 7. Overall Assessment

MRK is currently underperforming the S&P 500 significantly. Recent news suggests potential volatility, and technical indicators point to a short-term downtrend. While profitability remains strong, investors should closely monitor upcoming news and developments to assess the potential for future growth and stability. The negative expected return is a significant concern, suggesting a high level of uncertainty regarding long-term performance.

**Recommendation:** Given the recent negative trends, underperformance, and market volatility, a neutral to slightly bearish stance is warranted. Monitor upcoming news and earnings reports for signs of improvement.
